NDC 76420-772 Ketorocaine Lm Kit

The NDC code 76420-772 is assigned by the FDA to the product Ketorocaine Lm Kit which is a human prescription drug product labeled by Asclemed Usa, Inc.. The generic name of Ketorocaine Lm Kit is ketorolac tromethamine, lidocaine hydrochloride, bupivacaine hydrochloride, povidine iodine. The product's dosage form is kit and is administered via epidural; infiltration; intramuscular; intravenous; topical form. The product is distributed in a single package with assigned NDC code 76420-772-01 1 kit in 1 carton * 10 ml in 1 vial, single-dose (0409-1159-18) * .9 ml in 1 packet (67777-419-02) * 5 ml in 1 pouch * 10 ampule in 1 carton (55150-158-72) / 2 ml in 1 ampule * 1 ml in 1 vial (72266-118-01). This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).Acute Pain in Adult PatientsKetorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.Ketorolac tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the ketorolac tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac tromethamine injection and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION – Pharmaceutical Information for Ketorolac Tromethamine Injection). Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. Bupivacaine hydrochloride injection, USP is indicated for the production of local or regional anesthesia or analgesia for surgery, oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS.)Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of bupivacaine hydrochloride injection, USP in these patients.Bupivacaine hydrochloride injection, USP is not recommended for intravenous regional anesthesia (Bier Block). See WARNINGS.The routes of administration and indicated bupivacaine hydrochloride injection, USP concentrations are:local infiltration                          0.25%peripheral nerve block               0.25% and 0.5%retrobulbar block                       0.75%sympathetic block                     0.25%lumbar epidural                         0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) caudal                                        0.25% and 0.5%epidural test dose                      (see PRECAUTIONS)(See DOSAGE AND ADMINISTRATION for additional information.)Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of bupivacaine hydrochloride injection, USP.